Abarelix,R3827,PPI149 , >98% , 183552-38-7
CAS NO.：183552-38-7
Empirical Formula: C72H95ClN14O14
Molecular Weight: 1416.06
MDL number: MFCD06407663
EINECS: 1592732-453-0
| Pack Size | Price | Stock | Quantity |
| 10mg | RMB3168.00 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Boiling point: | 1688.4±65.0 °C(Predicted) |
| Density | 1.286±0.06 g/cm3(Predicted) |
| storage temp. | Store at -20°C |
| solubility | Methanol (Slightly), Water (Slightly) |
| pka | 9.82±0.15(Predicted) |
| form | Solid |
| color | White to Off-White |
| InChIKey | AIWRTTMUVOZGPW-HSPKUQOVSA-N |
Description and Uses
Abarelix is an antagonist of the gonadotropin releasing-hormone (Gn RH) receptor, and it was launched as an intramuscular injection for the palliative treatment of advanced symptomatic prostate cancer. Hormonal therapy of prostate cancer is based on the modulation of testosterone to achieve medical castration levels. The inhibition of GnRH activity causes the suppression of luteinizing hormone (LH) and follicle stimulating hormone (FSH) secretion, thereby reducing the secretion of testosterone by the testes. Abarelix is the first GnRH antagonist to reach its market. Hormonal therapy with GnRH agonists such as leuprolide, buserelin, and goserelin has been in use for over two decades. Drugs of this type achieve the suppression of LH and FSH by a feedback inhibition mechanism, which involves an initial rise in the LH and FSH levels and, consequently, in the levels of testosterone. A testosterone surge may induce a clinical tumor flare that worsens cancer-related symptoms. This phenomenon is observed in 4–33% of patients receiving a GnRH agonist. A GnRH antagonist such as abarelix acts by direct inhibition of LH and FSH secretion, which avoids the initial surge in serum testosterone concentrations. Abarelix is a decapeptide, and it is prepared by a typical coupling cycle for peptide synthesis using Boc-amino acids and a methylbenzhydrylamine (MBHA) resin. Abarelix has high binding affinity for GnRH receptor (Kd=0.1 nM). Following intramuscular administration of a 100 mg dose, abarelix is absorbed slowly with a Cmax of 43.4 ng/mL observed approximately 3 days after the injection and has a half-life of about 13 days. The apparent volume of distribution is over 4000 L, suggesting extensive distribution. Abarelix has high protein binding (96–99%), and it is primarily metabolized via hydrolysis of peptide bonds. Following a dose of 15 μg/kg in humans, approximately 13% of abarelix is recovered unchanged in the urine, with no detectable metabolites. The renal clearance of abarelix is 14.4 L/day following a 100 mg dose. Two randomized, open label, comparative clinical trials involving 348 patients demonstrated the efficacy of abarelix versus a GnRH agonist (leuprolide) as well as a combination of GnRH agonist and anti-androgen (leuprolide+bicalutamide). In these trials, both abarelix and the comparators reduced testosterone to medical castration levels (＜50 ng/dL) by day 29 of therapy in 94–98% of the patients. However, a significant difference was observed between the two groups for the occurrence of testosterone surge (0% in the abarelix group versus 82% in the GnRH agonist group) and for the rapidity of attaining castration levels (72% versus 0% on day 8 in the abarelix and GnRH agonist groups, respectively). Both groups maintained medical castration levels of testosterone with similar efficacy between days 29 and 85 of treatment. Abarelix was generally well tolerated in these trials. Approximately 3% of the patients experienced an immediate-onset allergic reaction. Other adverse events were similar to comparator controls and included hot flushes, sleep disturbance, pain, and breast enlargement. The recommended dosage of abarelix is 100 mg intramuscular injection on days 1, 15, and 29 of therapy, and every 4 weeks thereafter.
Gonad-stimulating principle; antagonist (LHRH).
